title: Treatment of fungal infections with semisynthetic derivatives of amphotericin B alpha.
abstract: AME appeared to be as effective as AmB in the treatment of mycoses in humans. AME was much less nephrotoxic than AmB, and was better tolerated in terms of rapid onset and reversible adverse reactions. AME may be more ototoxic than AmB. AME, even as AmB and OAME, may cause neurotoxicity and leukoencephalopathy, particularly when high doses are given for long periods.
authors.affiliation: Department of Internal Medicine, School of Medicine, University of California 95817.
authors.forename: P D
authors.initials: PD
authors.lastname: Hoeprich
authors.forename: N M
authors.initials: NM
authors.lastname: Flynn
authors.forename: M M
authors.initials: MM
authors.lastname: Kawachi
authors.forename: K K
authors.initials: KK
authors.lastname: Lee
authors.forename: R M
authors.initials: RM
authors.lastname: Lawrence
authors.forename: L K
authors.initials: LK
authors.lastname: Heath
authors.forename: C P
authors.initials: CP
authors.lastname: Schaffner
mesh_terms: D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D003047:Coccidioidomycosis / Q000188:drug therapy; D003453:Cryptococcosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; C017501:methylamphotericin B; D000666:Amphotericin B